Study to Assess the Safety, Tolerability, PK and PD of ABX1100

Exclusion Criteria

• •Known history or presence of any clinically significant hepatic, renal/genitourinary, gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological or hematological disease or condition.
• •History of any inherited or acquired skeletal muscle diseases (for example, Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy, Spinal Muscular Atrophy (SMA), Polymyositis, Rhabdomyolysis and Inclusion Body Myositis (IBM).
• •History of any inherited or acquired cardiac disease including congestive heart failure, ischemic heart disease, or arrhythmias; an abnormal ECG.
• •History of cancer within past 5 years, with the exception of treated or excised skin basal cell carcinoma.
• •Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks prior to the screening visit
• •Presence of any significant physical or organ abnormality.
• •Major surgery within 6 months prior to the start of the study.
• •Current smoker, recent history of smoking and/or use of any nicotine-containing products (within past 6 months).
• •A known history or positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody or human immunodeficiency virus (HIV) infection.
• •Currently participating in another investigational trial or have received any investigational drug within the past 30 days.
• •History of muscle biopsy within 1 month of Day 1 or planning to undergo non-study related muscle biopsies during study period.
• •History of coronary artery disease or cardiovascular disease.
• •History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• •Presence of any significant physical or organ abnormality as determined by the PI/Sub-Investigator.
• •Resting seated blood pressure \< 90/40 mmHg or \> 140/90 mmHg , unless deemed not clinically significant by the PI/Sub-Investigator.
• •Resting seated heart rate \< 45 bpm or \> 99 bpm, unless deemed not clinically significant by the PI/Sub-Investigator.
• •Intolerance to and/or difficulty with blood sampling through venipuncture.
• •Positive pregnancy test for female participants.
• •Currently participating in another investigational trial or have received any investigational drug within the past 30 days or 5 elimination half-lives of the investigational drug, whichever is longer, prior to dosing.
• •Requires a wheelchair or invasive ventilation.
• •Fridericia's corrected QT (QTcF) \> 450 ms for participants or history of QT interval prolongation unless deemed not clinically significant by the PI/Sub-Investigator.
• •Uncontrolled diabetes (Hemoglobin A1c \[HbA1c\] equal to or higher than 7.5%).
• •A known history or positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody or human immunodeficiency virus (HIV) infection.